ArticleCancer medicine2022
Evaluating adipose-derived stem cell exosomes as miRNA drug delivery systems for the treatment of bladder cancer.
Article in Cancer medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 45 citations in OpenAlex.
- Nanotechnology-enabled precision strategies for bladder cancer: from in vitro diagnostics to in vivo therapy.Journal of nanobiotechnology · 2026Review
- The multifaceted roles of microRNAs in nonalcoholic steatohepatitis: from pathogenic mechanisms to diagnostic and therapeutic opportunities.Frontiers in genetics · 2026Review
- Decoding the role of exosomes in bladder cancer: focusing on tumor progression and immune microenvironment modulation.Frontiers in oncology · 2026Review
- Advances in Exosome Research in Renal Cell Carcinoma: Mechanisms, Biomarkers, and Therapeutic Applications.International journal of nanomedicine · 2026Review
- Adipose-Derived Exosomes: mediators of crosstalk between Adipose tissue and cancer.Cancer biology & therapy · 2025Review
- Long-term resident adipose-derived stromal stem cells in the microenvironment remodeling BLCA cell stemness and EMT promotes bladder cancer progression.Scientific reports · 2025Article
- Exosome: an overview on enhanced biogenesis by small molecules.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- The role of exosomes in bladder cancer immunotherapy.Journal of the National Cancer Center · 2025Review
- Extracellular Vesicle-Based Drug Delivery Systems in Cancer Therapy.International journal of molecular sciences · 2025Review
- Exploring the Interaction of Tumor-Derived Exosomes and Mesenchymal Stem Cells in Tumor Biology.International journal of molecular sciences · 2025Review
- Mesenchymal Stem-Cell-Derived Exosomes as Novel Drug Carriers in Anti-Cancer Treatment: A Myth or Reality?Cells · 2025Review
- Epigenetic crosstalk between stem cells and tumors: mechanisms and emerging perspectives.American journal of stem cells · 2025Review
- Plant-derived Exosomes: Pioneering Breakthroughs in Therapeutics, Targeted Drug Delivery, and Regenerative Medicine.Pharmaceutical nanotechnology · 2025Review
- Unveiling the promise: Exosomes as game-changers in anti-infective therapy.Exploration (Beijing, China) · 2024Review
- From stem cells to extracellular vesicles: a new horizon in tissue engineering and regenerative medicine.Cytotechnology · 2024Review
- Article
- Potential Consequences of the Use of Adipose-Derived Stem Cells in the Treatment of Hepatocellular Carcinoma.International journal of molecular sciences · 2024Review
- Different origin-derived exosomes and their clinical advantages in cancer therapy.Frontiers in immunology · 2024Review
- Roles of adipose-derived stem cells and derived exosomes in therapeutic applications to testicular injury caused by cisplatin.PloS one · 2024Article
- Preparation of genetically or chemically engineered exosomes and their therapeutic effects in bone regeneration and anti-inflammation.Frontiers in bioengineering and biotechnology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesExosomes are essential mediators of intercellular communication as they transport proteins and RNAs between cells. Owing to their tumor-targeting capacity, immune compatibility, low toxicity, and long half-life, mesenchymal stem cell-derived exosomes have great potential for the development of novel antitumor strategies. In this context, the role of exosomes produced by adipose-derived mesenchymal stem cells (ADSCs) for the treatment of bladder cancer (BC) remains unclear. Here, we investigated the use of ADSCs as a source of therapeutic exosomes, as well as their efficacy in delivering the tumor suppressor miR-138-5p in BC.
methodsADSCs stably expressing miR-138-5p were established using Lentivirus infection, and ADSC-derived miR-138-5p exosomes (Exo-miR-138-5p) were isolated from the cell culture medium. The effect of Exo-miR-138-5p on BC cell migration, invasion, and proliferation was evaluated in vitro using wound healing, transwell invasion, and proliferation assays. The in vivo effect of Exo-miR-138-5p was investigated using a subcutaneous xenograft mouse model.
resultsExo-miR-138-5p prevented the migration, invasion, and proliferation of BC cells in vitro. Moreover, ADSC-derived exosomes could penetrate tumor tissues and successfully deliver miR-138-5p to suppress the growth of xenograft tumors in vivo.
conclusionsThe present results reveal that ADSC-derived exosomes are an effective delivery vehicle for small molecule drugs in vivo, and exosome-delivered miR-138-5p is a promising therapeutic agent for BC treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.